Zürcher Nachrichten - Revolution or mirage? Controversy surrounds new Alzheimer's drugs

EUR -
AED 3.832684
AFN 72.959602
ALL 98.462959
AMD 410.45402
ANG 1.873047
AOA 957.921829
ARS 1062.031565
AUD 1.668562
AWG 1.878277
AZN 1.784801
BAM 1.956057
BBD 2.098476
BDT 124.196346
BGN 1.95543
BHD 0.392152
BIF 3072.704402
BMD 1.043487
BND 1.411486
BOB 7.181945
BRL 6.350643
BSD 1.039337
BTN 88.357629
BWP 14.364891
BYN 3.401248
BYR 20452.35176
BZD 2.089175
CAD 1.498735
CDF 2994.808319
CHF 0.931781
CLF 0.03736
CLP 1030.865674
CNY 7.613704
CNH 7.60587
COP 4549.298739
CRC 524.369013
CUC 1.043487
CUP 27.652414
CVE 110.279514
CZK 25.108428
DJF 185.074358
DKK 7.458116
DOP 63.288329
DZD 140.667513
EGP 53.089373
ERN 15.65231
ETB 129.556951
FJD 2.417812
FKP 0.826423
GBP 0.829839
GEL 2.932642
GGP 0.826423
GHS 15.278011
GIP 0.826423
GMD 75.13081
GNF 8979.181761
GTQ 8.008054
GYD 217.438617
HKD 8.11073
HNL 26.382472
HRK 7.484837
HTG 135.967895
HUF 414.03543
IDR 16874.546735
ILS 3.801242
IMP 0.826423
INR 88.646863
IQD 1361.479186
IRR 43917.772492
ISK 145.170484
JEP 0.826423
JMD 162.611401
JOD 0.739936
JPY 163.242118
KES 134.177659
KGS 90.783029
KHR 4176.549681
KMF 486.395546
KPW 939.138018
KRW 1509.320727
KWD 0.321342
KYD 0.866114
KZT 545.821836
LAK 22747.993892
LBP 93069.24896
LKR 305.14016
LRD 188.634826
LSL 19.134218
LTL 3.081147
LVL 0.631195
LYD 5.106672
MAD 10.460077
MDL 19.14352
MGA 4903.645375
MKD 61.5431
MMK 3389.206159
MNT 3545.769827
MOP 8.320295
MRU 41.33344
MUR 49.25222
MVR 16.052761
MWK 1802.137182
MXN 20.931771
MYR 4.704048
MZN 66.682732
NAD 19.134218
NGN 1616.92545
NIO 38.245033
NOK 11.810924
NPR 141.372606
NZD 1.846749
OMR 0.401533
PAB 1.039337
PEN 3.870109
PGK 4.214555
PHP 61.430102
PKR 289.288974
PLN 4.258903
PYG 8104.066586
QAR 3.788799
RON 4.979106
RSD 117.045935
RUB 107.244587
RWF 1448.790677
SAR 3.91966
SBD 8.748133
SCR 14.551486
SDG 627.662417
SEK 11.505215
SGD 1.414024
SHP 0.826423
SLE 23.787187
SLL 21881.410825
SOS 593.978174
SRD 36.65877
STD 21598.081035
SVC 9.094197
SYP 2621.793487
SZL 19.129518
THB 35.780887
TJS 11.369896
TMT 3.662641
TND 3.311736
TOP 2.44395
TRY 36.710281
TTD 7.053928
TWD 34.050018
TZS 2468.324859
UAH 43.588037
UGX 3812.501768
USD 1.043487
UYU 46.356101
UZS 13399.76356
VES 53.713772
VND 26561.970104
VUV 123.884906
WST 2.882934
XAF 656.043343
XAG 0.035154
XAU 0.000398
XCD 2.820076
XDR 0.792804
XOF 656.043343
XPF 119.331742
YER 261.263155
ZAR 19.096059
ZMK 9392.640903
ZMW 28.762786
ZWL 336.002496
  • CMSD

    0.0000

    23.56

    0%

  • NGG

    0.8200

    58.5

    +1.4%

  • SCS

    -0.5800

    11.74

    -4.94%

  • RELX

    -0.3100

    45.47

    -0.68%

  • BCC

    -0.2600

    122.75

    -0.21%

  • AZN

    0.9100

    65.35

    +1.39%

  • GSK

    0.1700

    33.6

    +0.51%

  • RBGPF

    59.9600

    59.96

    +100%

  • CMSC

    0.0200

    23.86

    +0.08%

  • RIO

    -0.0900

    58.64

    -0.15%

  • BTI

    0.1131

    36.24

    +0.31%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • BCE

    0.0500

    23.16

    +0.22%

  • JRI

    0.1100

    12.06

    +0.91%

  • VOD

    0.0100

    8.39

    +0.12%

  • BP

    0.1900

    28.6

    +0.66%

Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Revolution or mirage? Controversy surrounds new Alzheimer's drugs / Photo: ALAIN JOCARD - AFP/File

Revolution or mirage? Controversy surrounds new Alzheimer's drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Text size:

For their defenders, the drugs lecanemab and donanemab represent the first real chance to fight the disease after decades of research -- for detractors, they are another disappointment after a long line of costly failures.

"We have turned a corner" thanks to these treatments, British biologist John Hardy, who has been studying Alzheimer's since the 1990s, told AFP.

Rob Howard, a professor of old age psychiatry at University College London, was on the other side.

"I think that the drugs have been used to raise false and unrealistic hopes in people with Alzheimer's disease and their families," he said.

These opposing statements sum up the entrenched positions on the recently introduced drugs for Alzheimer's, the most common form of dementia which millions of people across the world suffer from.

Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.

The controversy has seen countries take different stances on whether to approve the drugs or not.

The United States gave the green light to lecanemab in 2023, then donanemab earlier this year.

However the European Union rejected lecanemab in July, a bad omen for donanemab's chance of approval.

Last month, the UK steered a middle course, approving the use of lecanemab but not making it available on the state National Health Service.

What no one denies is that the two drugs are the most effective Alzheimer's treatments ever -- but their effectiveness is limited.

Both appear to reduce cognitive decline in patients at the onset of their disease by around 30 percent.

While that may seem high, it represents a relatively small difference over the year-and-a-half period when the studies were carried out.

"The benefits are so tiny as to be practically invisible in an individual patient," Howard said.

- Exorbitant cost -

For critics, there are not enough benefits to outweigh the risks of the drugs, which can sometimes cause brain swelling or bleeding that in rare cases has proved fatal.

And they are very expensive. At the prices being charged by Biogen and Eisai in the United States, lecanemab would cost 133 billion euros ($148 billion) if given to all eligible patients in the EU, according to a 2023 study.

Advocates of the drugs, including many neurologists, believe they can offer patients a few more precious months of autonomy.

They also believe that the effectiveness of the drugs could be multiplied if patients started taking them earlier in the disease's progression. This could soon be more practicable as research on diagnosing Alzheimer's more quickly has recently been making significant strides.

The differing national policies could also mean that poorer patients are left behind.

"We will see rich people going to the US" for the drugs, Hardy said.

The debate can be traced back in part to a seminal 1992 article by Hardy about how the disease actually works.

The article argues that clumps of protein called amyloid plaques -- a constant in the brains of Alzheimer's patients -- are not just one element among others, but the main factor triggering the disease.

Over the decades, many drugs targeting these amyloid plaques were developed, all of which failed -- until lecanemab and donanemab.

- Pressure from families -

The scepticism from some quarters about the new drugs could be because the previous ones were defended and even lauded by some, despite their ineffectiveness.

Christian Guy-Coichard, the head of French organisation Formindep which monitors medical conflicts of interest, accused Alzheimer's groups, researchers and pharmaceutical firms of being too close.

But France Alzheimer deputy director Benoit Durand said that very little of its funding came from Biogen/Eisai or Eli Lilly, instead pointing towards pressure for new treatments from patients' families.

"They don't understand" the EU's decision to turn down a breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due to the setbacks.

Even within the pharmaceutical industry, some admit that past failures have not necessarily helped build trust.

A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in the US in 2021 before being withdrawn.

"The Aduhelm studies were a mess," the doctor said.

The aftermath "did a lot of harm and sowed chaos in the discipline", the doctor added, pointing the finger at Biogen.

In response, Biogen told AFP that it was complying with "the principles of scientific research as well as legal and regulatory requirements".

But the Eli Lilly doctor defended the new treatments all the same, urging people to look to the future, not the past.

Like other specialists, he also acknowledged that other mechanisms besides amyloids that could be behind Alzheimer's need to be explored.

Given the disease's complexity, it is unlikely that "single-target treatments will achieve substantially larger effects" than lecanemab and donanemab, a group of experts wrote in the Journal of Prevention of Alzheimer's Disease last month.

But the new drugs are a "critical step" in Alzheimer's treatment, they added.

Y.Keller--NZN